ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

ANG1005 Demonstrates Activity In Patients with Brain Metastases

November 29, 2013

Study Finds Gene Expression Test Predicts Stage I or II Recurrence

August 30, 2013

NCI To Fund 23 CHOPs, More Singles Than Multiples; ACCC Expresses Concern

August 8, 1980

Women’s Caucus Calls For Wide Mammogram Payment

March 18, 1994

RFPs Available, Contract Awards, Sole Source Negotiations

June 25, 1976

Minnesota Study Aimed At Finding Final Answer On Hemoccult Screening

July 24, 1987